Lab Name: Mahmud Lab (Study and Brew Blood to Treat Leukemia)
Principal Investigator: Nadim Mahmud, MD, PhD
Research Area: Stem Cell Expansion, Hematopoiesis, Stem Cell Transplantation, Cell based therapy, & Leukemia
1. Generating Human Cord-Blood-Derived Functional Megakaryocytes and Platelets.
2. Cord blood stem cell expansion using epigenetic modifier to understand biology of stem cell fate.
3. Use of expanded cord blood graft for hematologic malignancies and other cell based therapy
4. Leukemia stem cell (LSC) fate choice and development of chemical probe to target LSC as therapeutics.
5. Development of “off the shelf” bridge graft as a therapy for post radiation/chemotherapy bone marrow suppression (Proof of Concept: Chancellor’s Innovation Award)
Link to Lab
Lab Name: Laboratory of Translational Research in Sickle Cell Disease and other Hematologic Disorders
Principal Investigator: Victor Gordeuk, MD
1. Genetic modifiers of anemia, kidney function, and metabolism in sickle cell disease and other hematologic disorders
2. Regulation of iron metabolism in sickle cell disease, congenital polycythemia and hereditary iron overload
3. Contribution of the hypoxic response to complications of hematologic disorders
4. Hydroxyurea therapy for sickle cell disease in Africa
Lab Name: Saraf Lab (Pathways of Cell-free hemoglobin in Sickle Cell Nephropathy)
Principal Investigator: Santosh Saraf, MD
- Evaluating the effects of genetic modifiers in cell-free hemoglobin/heme processing in the pathophysiology of sickle cell disease-related kidney damage
- In vivo and in vitro testing of cell-free hemoglobin/heme effects on endothelial function
- Developing therapies to mitigate cell-free hemoglobin/heme exposure to the kidney
Lab Name: Gentile Lab
Principal Investigator: Saverio Gentile, MD, PhD
Research Area: The role of ion channels in cancer and on developing an anticancer therapeutic strategy by pharmacological targeting ion channels
We have discovered that cancer cells (independently of their histogenesis) can aberrantly express specific Potassium channels (K+Ch) which render cancers susceptible to targeting and growth arrest. Also, pharmacological targeting of these K+Ch with selective small molecules already available, affects several hallmarks of cancer including cell proliferation and motility, metabolism and drug resistance without significant side effects. Furthermore, we discovered that targeting K+Ch potentiates efficacy of drugs that are currently in use for cancer therapy. Our studies are a key step in translating this innovative approach into an effective targeted therapy that improves outcomes and reduces treatment-related morbidity.
- Recent Grants & Awards Page: https://chicago.medicine.uic.edu/departments/academic-departments/medicine/hematologyoncology/research/recent-grants-awards/